Peripheral immune–vascular correlates of suicidal thoughts and behaviors in bipolar disorder and schizophrenia: cross-sectional and prospective analyses from the FACE-BD and FACE-SZ cohorts

Aiste Lengvenyte, Wahid Boukouaci, Ching-Lien Wu, Bruno Aouizerate, Frank Bellivier, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau, Clément Dondé, Caroline Dubertet, Bruno Etain, Eric Fakra, Emmanuel Haffen, Dominique Januel, Theo Korchia, Antoine Lefrere, Pierre-Michel Llorca, David Misdrahi, Mircea Polosan, Romain Rey, Paul Roux, Ludovic Samalin, Franck Schürhoff, Raymund Schwan, David Szekely, Etienne Very, Michel Walter, Antoine Yrondi, Caroline Barau, Emilie Olié, Marion Leboyer, Philippe Courtet
Brain, Behavior, and Immunity. 2026-08-01; 136: 106783
DOI: 10.1016/j.bbi.2026.106783

1. Brain Behav Immun. 2026 Apr 27;136:106783. doi: 10.1016/j.bbi.2026.106783.
Online ahead of print.

Peripheral immune-vascular correlates of suicidal thoughts and behaviors in
bipolar disorder and schizophrenia: cross-sectional and prospective analyses
from the FACE-BD and FACE-SZ cohorts.

Lengvenyte A(1), Boukouaci W(2), Wu CL(2), Aouizerate B(3), Bellivier F(4),
Berna F(5), Capdevielle D(6), Chereau I(7), Dondé C(8), Dubertet C(9), Etain
B(4), Fakra E(10), Haffen E(11), Januel D(12), Korchia T(13), Lefrere A(14),
Llorca PM(7), Misdrahi D(15), Polosan M(16), Rey R(17), Roux P(18), Samalin
L(7), Schürhoff F(19), Schwan R(20), Szekely D(21), Very E(22), Walter M(23),
Yrondi A(24), Barau C(25); FondaMental Advanced Centres of Expertise in Bipolar
Disorders (FACE-BD) Collaborators; FondaMental Advanced Center of Expertise for
Schizophrenia (FACE-SZ) collaborators.

Collaborators: Olié E(26), Leboyer M(2), Courtet P(26).

Author information:
(1)Fondation FondaMental, Créteil, France; Department of Emergency Psychiatry
and Acute Care, Lapeyronie Hospital, Centre Hospitalier Universitaire de
Montpellier, Institute of Functional Genomics, University of Montpellier,
National Centre for Scientific Research, French National Institute of Health and
Medical Research, Montpellier, France. Electronic address:
.
(2)Fondation FondaMental, Créteil, France; Université Paris Est Créteil (UPEC),
INSERM, Institut Henri Mondor the Recherche Biomédicale, Laboratoire
Neuro-Psychiatrie Translationnelle, Assistance Publique Hôpitaux de Paris,
Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de
Psychiatrie et d’Addictologie, Créteil, France.
(3)Fondation FondaMental, Créteil, France; Pôle de Psychiatrie Générale et
Universitaire, Centre Hospitalier Charles Perrens, Laboratoire de Nutrition et
Neurobiologie intégrée, NutriNeuro (UMR INRAe 1286), Université de Bordeaux,
Bordeaux, France.
(4)Fondation FondaMental, Créteil, France; Université Paris Cité, INSERM,
Optimisation Thérapeutique en Neuropharmacologie, OPTEN U1144, Département de
Psychiatrie et de Médecine Addictologique, Hôpitaux Lariboisière-Fernand Widal,
GHU APHP.Nord – Université Paris Cité, Paris F-75010, France.
(5)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1329, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(6)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm 1061, Montpellier, France.
(7)Fondation FondaMental, Créteil, France; Service de Psychiatrie Adulte, CHU
Clermont-Ferrand, Université Clermont-Auvergne, CNRS, Clermont-Auvergne INP,
Institut Pascal (UMR6602), Clermont-Ferrand, France.
(8)Fondation FondaMental, Créteil, France; Univ. Grenoble Alpes, Inserm U1216,
Psychiatry Department, CH Alpes Isere, CHU Grenoble F-38000 Grenoble, France.
(9)Fondation FondaMental, Créteil, France; AP-HP, Groupe Hospitalo-universitaire
AP-HP Nord, DMU ESPRIT, Service de Psychiatrie et Addictologie, Hôpital Louis
Mourier, Colombes, Université de Paris Inserm UMR1266, Sorbonne Paris Cité,
Faculté de Médecine, France.
(10)Fondation FondaMental, Créteil, France; Department of Psychiatry, University
Hospital of Saint-Etienne, Saint-Etienne, France.
(11)Fondation FondaMental, Créteil, France; Univ Marie et Louis Pasteur, UMR
INSERM 1322 LINC, Besançon, service de psychiatrie de l’adulte, CIC-1431 INSERM,
CHU de Besançon F-25000, France.
(12)Fondation FondaMental, Créteil, France; Université Sorbonne Paris Nord
93017, Bobigny cedex, Département de recherche clinique, Pole universitaire03
G03, EPS Ville Evrard Neuilly sur Marne, 93330, France.
(13)Fondation FondaMental, Créteil, France; AP-HM, Service Universitaire de
psychiatrie et d’addictologie (Pr Lançon), Hôpital Sainte Marguerite, 13009
Marseille, France.
(14)Fondation FondaMental, Créteil, France; Pôle de Psychiatrie, Assistance
Publique Hôpitaux de Marseille, NT-UMR7289, CNRS Aix-Marseille Université,
Marseille, France.
(15)Fondation FondaMental, Créteil, France; University of Bordeaux, Aquitaine
Institute for Cognitive and Integrative Neuroscience (CNRS UMR 5287-INCIA),
Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France.
(16)Fondation FondaMental, Créteil, France; Univ. Grenoble Alpes, Inserm, U1216,
CHU Grenoble Alpes, Grenoble Institut Neurosciences, 38000 Grenoble, France.
(17)Fondation FondaMental, Créteil, France; INSERM U1028, CNRS UMR5292, Centre
de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe
PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678
Bron Cedex, France.
(18)Fondation FondaMental, Créteil, France; Service universitaire de psychiatrie
d’adulte et d’addictologie, Centre Hospitalier de Versailles, 177 rue de
Versailles, 78157 Le Chesnay, France, MOODS team, INSERM UMR1018, CESP, Faculté
de Médecine Paris-Saclay, Université de Versailles Saint-Quentin-En-Yvelines,
Université Paris-Saclay, Villejuif, France.
(19)Fondation FondaMental, Créteil, France; Université Paris Est Créteil (UPEC),
INSERM, Institut Henri Mondor the Recherche Biomédicale, Laboratoire
Neuro-Psychiatrie Translationnelle, Créteil, Assistance Publique Hôpitaux de
Paris, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de
Psychiatrie et d’Addictologie, France.
(20)Fondation FondaMental, Créteil, France; Université de Lorraine, Centre
Psychothérapique de Nancy, Inserm U1254, Nancy, France.
(21)Fondation FondaMental, Créteil, France; Service de Psychiatrie, Centre
Hospitalier Princesse Grace, 98000 Monaco, France.
(22)Fondation FondaMental, Créteil, France; Department of Psychiatry,
Psychotherapies, Art-therapy, Toulouse University Hospital, Equipe de Recherche
sur les Rationalités Philosophiques et les Savoirs – EA3051, Université de
Toulouse – Jean Jaurès, Toulouse, France.
(23)Fondation FondaMental, Créteil, France; Service Hospitalo-Universitaire de
Psychiatrie Générale et de Réhabilitation Psycho Sociale 29G01 et 29G02, CHRU de
Brest, Hôpital de Bohars, Brest, France.
(24)Fondation FondaMental, Créteil, France; Service de psychiatrie et de
psychologie médicale, Centre expert dépression résistante et trouble bipolaire,
CHU de Toulouse, Hôpital Purpan, Centre de neuroimagerie de Toulouse (ToNIC),
Université de Toulouse, Inserm 1214, UPS, Toulouse, France.
(25)Plateforme de ressources biologiques, Hôpital Henri Mondor, Université Paris
Est Créteil, Creteil, France.
(26)Fondation FondaMental, Créteil, France; Department of Emergency Psychiatry
and Acute Care, Lapeyronie Hospital, Centre Hospitalier Universitaire de
Montpellier, Institute of Functional Genomics, University of Montpellier,
National Centre for Scientific Research, French National Institute of Health and
Medical Research, Montpellier, France.

BACKGROUND: Bipolar disorder (BD) and schizophrenia-spectrum disorders (SZ) are
associated with high rates of suicidal ideation (SI) and suicide attempts (SA).
Peripheral immune-vascular abnormalities may contribute to suicidal
vulnerability in these disorders, but their specificity, temporal meaning, and
diagnostic patterning remain unclear.
METHODS: We quantified 28 peripheral immune-vascular variables
(cytokines/chemokines, vascular-injury markers, blood counts, lipids) in 980
French FACE (FondaMental Advanced Centres of Expertise) outpatients with BD
(n = 529) or SZ (n = 451). Elastic-net logistic regression and partial
least-squares regression for binary outcomes examined associations with SA,
baseline SI, and SI over 12 months in pooled and diagnosis-stratified samples.
Models adjusted for age, sex, and body mass index, with sensitivity analyses for
depression severity, medication classes, smoking, phenotype overlap, attrition,
and missing data.
RESULTS: In pooled analyses, SA was associated with higher vascular endothelial
growth factor; stratified analyses suggested this signal was mainly driven by BD
(OR = 1.33, 95% CI 1.08-1.64). In SZ, SA showed weaker platelet/SAA-related
associations. Baseline SI showed more consistent multivariate signals than
individual analytes; in BD, higher IL-7 and SAA remained associated with SI
after adjustment, whereas SZ findings were more medication-sensitive. SI over
12 months showed the least stable associations; in BD, lower IL-7 was associated
with follow-up SI (OR = 0.72, 95% CI 0.54-0.96). Internal validation indicated
stronger performance for baseline SI than for SA or follow-up SI.
CONCLUSIONS: We found modest, phenotype-dependent and partly diagnosis-specific
peripheral immune-vascular correlates of SI and SA in BD and SZ. Replication and
direct biological validation are needed.

DOI: 10.1016/j.bbi.2026.106783
PMID: 42055221

Conflict of interest statement: Declaration of competing interest The authors
declare that they have no known competing financial interests or personal
relationships that could have appeared to influence the work reported in this
paper.